



## Speaker Biographies



**William A. Hawkins, III (“Bill”)** joined Immucor, Inc., a TPG portfolio company, as CEO in October 2011. He also serves as Senior Advisor to TPG’s Healthcare Division. Prior to joining Immucor and TPG, Bill served as Chairman and CEO of Medtronic (NYSE) from 2007 to 2011, one of the world’s largest and most innovative medical technology companies. He was President and COO of Medtronic from 2004 to 2008, and served as Senior Vice President and President of Vascular from 2001 to 2004.

Prior to Medtronic, Bill was President and CEO of Novoste Corp. (NASDAQ) from 1998 to 2001. He served as Corporate Vice President at American Home Products from 1997 to 1998. Bill was President of Ethicon Endo-Surgery for Johnson & Johnson from 1995 to 1997. Previous to that, he held executive positions at Guidant Corp., and Eli Lilly & Co. He began his medical technology career with Carolina Medical Electronics in 1977.

Bill graduated from Duke University in 1976 with a bachelor’s degree in electrical and biomedical engineering. Bill went on to earn an MBA from the Darden School of Business, University of Virginia in 1982.

Bill serves on the American Institute of Medical Bioengineering (AIMBE) Board – President, AdvaMed DX Board, Duke University Board of Trustees, Duke University Health System Board, KeraNetics Board – Chairman, Medical Device Innovation Consortium (MDIC) Board – Chairman, and Thoratec Corporation (NYSE) Board. He also serves on the Arboretum Ventures Advisory Board, Radius Ventures Advisory Board, Accuitive Medical Ventures Advisory Board, and nContact Surgery Advisory Board.



**Ravi Bellamkonda**, PhD holds the Wallace H. Coulter Endowed Chair and is the Departmental Chair of the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology/Emory University. The Department of Biomedical Engineering has consistently ranked in the top five programs at the graduate and undergraduate levels in the country.

He is also President of the American Institute for Medical and Biological Engineering (AIMBE), a society for bioengineers from academia and industry based in Washington DC. Ravi has won numerous awards and was recognized as the 2014 Clemson Award winner for Applied Biomaterials Research by the Society for Biomaterials. Ravi is actively engaged with programs promoting educational and research innovation at Georgia Tech and the Emory School of Medicine. He serves as the Co-PI for Georgia Tech's Innovation Hub on an NSF-funded regional I-Corp Center and is the Georgia Tech Co-PI for the Atlanta Clinical & Translational Science Institute.

He directs the Neurological Biomaterials and Cancer Therapeutics Laboratory, a part of the Laboratory for Neuroengineering in the Department of Biomedical Engineering. His research interests lie at the intersection of biomaterials and nanotechnology as applied to the nervous system including peripheral and central nerve repair, brain tumor therapy, and neural interfacing. He also directs a T32 training grant called Rational Design of Biomaterials, and a Graduate Leadership Program for Bioengineering/Biomedical Engineering graduate students and is a Georgia Cancer Coalition Distinguished Scholar. Finally, Ravi was recognized as 'Best Professor' by the BME undergraduate Student Advisory Board for his contributions to undergraduate teaching and mentoring. Ravi earned his PhD from Brown University, and continued his education as a Postdoctoral Fellow at MIT.



**Lilly Immergluck**, MD, FAAP is an Associate Professor of Pediatrics and Assistant Professor of Microbiology, Biochemistry, and Immunology at Morehouse School of Medicine. She is also an Assistant Professor of Clinical Pediatrics at Emory University, Pediatric Infectious Disease Specialist at Children's Healthcare of Atlanta, and Director of the MRSA Research Treatment Center for Atlanta.

She is a practicing general pediatrician and pediatric infectious disease specialist. She is also a physician scientist whose clinical translational research projects are centered on decreasing both community and hospital acquired infections in children with emphasis on prevention of antibiotic resistant infections, particularly among medically underserved populations. She has studied the clinical and molecular epidemiology of children affected by community associated methicillin resistant *Staphylococcus aureus* (MRSA) for more than 15 years.

Currently, Lilly is part of a NIH-funded multi-center randomized control study to understand what treatment modality is best to heal skin and soft tissue infections due to community-associated MRSA. She also is actively involved in epidemiology research related to vaccine preventable conditions and has

a special interest in working to decrease health disparities in this area. She is part of the Centers for Disease Control and Prevention's effort to understand the impact of vaccination in preventing rotaviral related diarrheal diseases in infants and children. Most recently, she has also been exploring mechanisms to work with industry to develop and launch products which will reduce preventable infections in children.



**Wilbur Lam, MD, PhD** is an Assistant Professor in the Department of Pediatrics, Division of Hematology/Oncology at the Emory University School of Medicine and at the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology/Emory University. With a Bachelors of Arts from Rice University and a PhD from UCSF, he has a background as a physician-scientist-engineer with knowledge of pediatric hematology/oncology and bioengineering. His research interests involve developing and applying novel technologies in order to research, design, and treat hematologic and oncologic processes.

He works in a lab that is interested in the development of new devices for children, blood diseases, and cancer. Their lab projects aim to develop novel technologies for a variety of diseases that are becoming prevalent and damaging to society, such as sickle cell, cancer, and leukemia.



**Lou Malice** has worked in the field of medical device research and development, manufacturing, supply chain management, quality and regulatory, and IT for more than 30 years. He is now an active consultant in the Atlanta medical device community.

Lou recently retired from his position as COO of Endochoice, Inc., a manufacturer and distributor of products serving gastro-intestinal professionals. As an original member of management, Lou served as COO of EndoChoice since its inception, helping to guide the company's growth from seven to over 400 employees. EndoChoice was recognized by *INC Magazine* as one of the fastest growing medtech companies for four consecutive years.

From 2003 to 2007, Lou served as Co-CEO of a successful start-up, American Breast Care (ABC), LP, a manufacturer/distributor of products for women after breast surgery. Prior to ABC, Lou was employed at Coloplast Corporation, a subsidiary of Coloplast AS (Denmark), a \$1 billion manufacturer of Ostomy, Continence, Wound Care, Skin Care, and Breast Care products. He held positions of Executive Vice President Operations and Division President during his tenure from 1993 to 2002. Prior to 1993, he held positions in Engineering, Manufacturing, Development, Logistics, and Senior Management.

Lou is a native of Atlanta and obtained his BS in Industrial Management from Georgia Institute of Technology. He also holds four U.S. Patents.



**Grace Powers** joined C.R. Bard, Inc. as a Regulatory Affairs Manager in 2010. C.R. Bard is a medical device company that is a leader in products that focus on Disease State Management in three key areas: Vascular, Urology, and Oncology. Grace manages a team of eight individuals that complete all of the regulatory activities for international submissions for over 6,000 medical products sold in nearly 100 different countries.

Prior to C.R. Bard, Grace was employed for over six years as a Regulatory Affairs Specialist at CardioMEMS, Inc., a medical device company that develops implantable wireless blood pressure sensors. Prior to working in Regulatory Affairs, Grace held the position of Senior Biomedical Engineer at CardioMEMS. Before joining CardioMEMS, Grace was an Associate Engineer at Novoste Corporation.

Grace holds the U.S. and Global RAC and was named the 2009 Emerging Leader of the Year by Georgia Bio. She earned her Bachelor's degree in Biomedical Engineering from Vanderbilt University. She also attended UCLA for her Master's in Biomedical Engineering. Most recently, she earned her MBA from the Georgia Tech College of Management. Grace lives in Smyrna, GA with her husband and two children.



**Todd Sherer**, PhD, CLP is Associate Vice President for Research Administration and Executive Director of the Office of Technology Transfer at Emory University. He leads a team of 20 focused on creating value from intellectual property developed by Emory researchers.

Since joining Emory in 2003, Todd has expanded the program by twelve staff, instituted a commercially oriented product pipeline to highlight Emory's varied portfolio, and created an in-house patent department to reduce costs and better align patent work with research activity. Licensing revenues have exceeded \$700 million since Todd joined the office. He also worked with colleagues to monetize downstream licensing revenues on an Emory-discovered molecule that is now part of the leading AIDS drug cocktail – resulting in a \$540 million, one-time payment.

Todd is Past President for the Association of University Technology Managers (AUTM). He is also on the Board of Directors of Southeast BIO (SEBIO). Todd is a Registered Patent Agent with the United States Patent and Trademark Office. He is also a Registered Technology Transfer Professional (RTTP) and a Certified Licensing Professional (CLP).